cbdMD, Inc. (AMEX:YCBD) Q2 2025 Earnings Call Transcript
Access earnings results, analyst expectations, report, slides, earnings call, and transcript.
Overview
The earnings call reveals mixed signals: a slight revenue increase and improved cost structure are positive, but regulatory challenges and liquidity risks temper optimism. The new product expansion and capital structure improvements could yield future benefits, yet current financial constraints and market competition pose challenges. Analysts' cautious sentiment in the Q&A further supports a neutral outlook.
Key Financial Performance
Total Net Sales $4.7 million, an 8.6% increase year-over-year; driven by a 22% increase in wholesale revenue.
E-commerce Sales $3.6 million, flat year-over-year; represented 77% of total net sales, down from 83% in the prior year.
Wholesale Revenue $1.1 million, up 22% year-over-year from $750,000; attributed to adding new sales reps and focusing on high-quality partnerships.
Gross Profit Margin 62%, maintained healthy margins despite increased warehouse rent and one-time CAM costs.
SG&A Expenses $3.5 million, down from $4.1 million year-over-year; reduction due to lower payroll, professional fees, and elimination of headquarters lease.
Loss from Operations Approximately $485,000, improved from a $1.5 million loss year-over-year; attributed to cost structure improvements.
Net Loss $480,000, improved from a loss of $3 million year-over-year; primarily due to adjustments in operating expenses.
Non-GAAP Adjusted EBITDA Loss $197,000, improved from a loss of $680,000 year-over-year; attributed to management's focus on cost structure and profitability.
Cash and Cash Equivalents Approximately $1.7 million, down from $2.4 million; impacted by $1 million of accrued preferred dividends.
Working Capital Negative $3.7 million, compared to a negative $2.2 million; primarily due to accrued preferred dividends.
Adjusted Net Working Capital Positive $2.8 million as of March 2025, compared to $2.4 million as of September 2024; excluding accrued dividends.
Inventory Investment Approximately $400,000 during the quarter; aimed at bolstering key SKUs and supporting Oasis inventory rollout.
You have reached the limit. Sign up to access full content
Get started
Operating Highlights
Herbal Oasis: Scaling Herbal Oasis, our hemp derived THC seltzer brand, which has recently won awards and expanded distribution in Alabama, Florida, and North Carolina.
Wholesale Revenue Growth: Wholesale revenue is up 13% on a trailing 12-month basis, with new sales reps added to focus on high-quality partnerships.
SG&A Expenses Reduction: SG&A expenses for Q2 2025 totaled $3.5 million, down from $4.1 million in the prior year, due to payroll reductions and cost-saving initiatives.
Inventory Investment: Invested approximately $400,000 in inventory during the quarter to bolster key SKUs and support the Oasis rollout.
Capital Restructuring: Successful conversion of Series A Preferred Stock and reverse stock split, improving capital structure and eliminating $4 million in annual dividends.
Future M&A Opportunities: The capital restructuring opens doors for future strategic opportunities, including potential M&A to expand into new categories and customer segments.
You have reached the limit. Sign up to access full content
Get started
Risk or Challenges
Earnings Expectations: cbdMD, Inc. missed earnings expectations with a reported EPS of $-1.9, compared to expectations of $-1.6.
Regulatory Issues: The company is tracking active legislation in over 23 states, indicating potential regulatory challenges that could impact their operations.
Supply Chain Challenges: The rollout momentum for their THC seltzer brand slowed in Q2 due to legislative activity, suggesting supply chain and regulatory challenges.
Economic Factors: The company is operating in a competitive market where alcohol consumption is declining, and consumers are seeking functional alternatives, which may affect sales.
Capital Structure Risks: The company underwent a complex capital restructuring involving the conversion of Series A Preferred Stock and a reverse stock split, which indicates potential risks in maintaining compliance with NYSE American listing standards.
Working Capital: As of March 31, 2025, the company reported negative working capital of approximately $3.7 million, which poses a risk to operational flexibility.
Cash Flow Management: The company is focused on managing cash carefully, with a cash balance of approximately $1.7 million, indicating potential liquidity risks.
You have reached the limit. Sign up to access full content
Get started
Guidance & Outlook
Revenue Growth Initiatives: cbdMD is focused on three key areas to drive revenue growth: enhancing direct-to-consumer business, expanding wholesale business, and scaling the Herbal Oasis THC seltzer brand.
Capital Structure Improvement: The successful conversion of Series A Preferred Stock and a reverse stock split has simplified the capital structure, eliminated $4 million in annual dividends, and raised pro forma non-GAAP adjusted book value to over $7 million.
Market Expansion: cbdMD is ramping up distribution for its Herbal Oasis brand, with new markets and retail placements in the pipeline.
M&A Opportunities: The company is evaluating potential M&A opportunities to expand into new categories and customer segments.
Profitability Commitment: cbdMD is committed to delivering profitable growth in 2025 and is focused on returning to positive income and EBITDA in the second half of the year.
Financial Position: The company has approximately $1.7 million in cash, no debt, and a clean capital structure, positioning it favorably compared to peers.
Revenue Expectations: Total net sales for Q2 2025 were $4.7 million, with a focus on improving quarterly revenue numbers moving forward.
EBITDA Improvement: Non-GAAP adjusted EBITDA loss improved to $197,000 in Q2 2025 from $680,000 in Q2 2024, reflecting better cost management.
You have reached the limit. Sign up to access full content
Get started
Shareholder Return Plan
Accrued Dividends: Approximately $6.7 million in accrued dividends were converted into common stock.
Annual Dividends Obligation: The conversion eliminated $4 million in annual dividends.
Share Count Post-Conversion: Approximately 8.9 million shares of common stock outstanding after conversion.
Debt Status: No debt and no warrant overhang.
Preferred Stock Conversion: Conversion of Series A Preferred Stock simplified capital structure.
You have reached the limit. Sign up to access full content
Get started
Key Q&A
Q:Could you give us a little bit more color on the expansion of the Herbal Oasis brand?
A:We started discussions with distributors in December and began shipping in March. Regulatory issues slowed progress, but we are actively working with key distribution networks and expanding beyond the Southeast.
Q:Should we expect Herbal Oasis to be a key driver of growth in 2026, or can we see material impact in the back half of this year?
A:We should start seeing good contribution from the brand towards the back end of this year.
Q:How do you expect the conversion of preferred into common equity to impact your strategy moving forward?
A:The conversion improves our capital structure, allowing us to maintain our NYSE listing and pursue strategic investments and M&A opportunities.
Q:Are you comfortable with the guidance that liquidity will be sufficient through the end of fiscal 2026?
A:Yes, we are comfortable with our working capital and liquidity outlook.
Q:What types of strategic activity do you find most attractive moving forward?
A:We are looking for opportunities with cost synergies and customer overlap, both within and outside the cannabinoid space.
Q:What kind of financial and operating performance metrics can you offer for the Herbal Oasis product set?
A:The revenue impact started at the end of the March quarter, and we expect to see growth moving through the third quarter. Gross margins are not the same as our core business, but we view it as incremental contribution.
Q:Review of Unclear Management Responses
A:Management did not provide specific financial and operating performance metrics for the Herbal Oasis product set, indicating that more disclosure will come as they reach materiality thresholds.
You have reached the limit. Sign up to access full content
Get started
Earnings Word Cloud
The most frequently occurring keywords in this quarter's earning call
America exchange
American threshold
Gaylian cbdMD
Inc expectation
Instructions conference
NYC America
NYSE listing
Officer Gaylian
PL priority
Preferred Stock
SGA income
Series Preferred
Stock split
THC seltzer
Transcript cbdMD
approval
brand
cbdMD Inc
cbdMD term
detail sale
expectation afternoon
expense loss
forma book
future
industry SGA
inventory
law afternoon
month SGA
sale increase
share
stock split
working capital
YCBD Transcript
cbdMD, Inc. (YCBD) Q2 2026 Earnings Call Transcript
Unknown5-14
The earnings call presented mixed signals. While revenue growth and strategic acquisitions like Bluebird Botanicals are positive, declining gross margins and increased operational losses raise concerns. The Q&A indicated management's optimism about future synergies and improved EBITDA, but lacked clarity on key metrics and timelines. The cautious stance on reverse stock split and challenges in regulatory environments add uncertainty. Given these factors, the stock price reaction is likely to remain stable, with no strong catalysts for significant movement in either direction over the next two weeks.
cbdMD, Inc. (YCBD) Q1 2026 Earnings Call Transcript
Unknown2-17
The earnings call reflects mixed signals: a 12% revenue increase and improved liquidity are positive, but declining margins, a net loss, and integration risks weigh negatively. The Q&A reveals uncertainty, particularly around the Herbal Oasis product line, and management's vague responses may concern investors. The lack of market cap data limits assessment of stock reaction magnitude, but overall, the sentiment aligns with a neutral prediction given the balanced positives and negatives.
cbdMD, Inc. (YCBD) Q4 2025 Earnings Call Transcript
Unknown12-19
The earnings call presents a mixed picture: improved operating results and gross margin are positive, but declining e-commerce sales and marketing inefficiencies are concerning. The Q&A section reveals cautious optimism about regulatory developments but lacks clarity on strategic plans. While the elimination of preferred dividend obligations and growth in wholesale sales are positives, the company's reliance on equity financing and potential dilution remain concerns. Overall, the sentiment is neutral due to balanced positive and negative aspects, with no clear catalyst for a strong stock price movement in either direction.
cbdMD, Inc. (AMEX:YCBD) Q2 2025 Earnings Call Transcript
Unknown5-17
The earnings call reveals mixed signals: a slight revenue increase and improved cost structure are positive, but regulatory challenges and liquidity risks temper optimism. The new product expansion and capital structure improvements could yield future benefits, yet current financial constraints and market competition pose challenges. Analysts' cautious sentiment in the Q&A further supports a neutral outlook.
YCBD Report
Frequently Asked Questions
Where does this earnings call transcript come from?
All transcripts are sourced directly from the official live webcast or the company’s official investor relations website. We use the exact words spoken during the call with no paraphrasing of the core discussion.
How soon is the transcript available after the earnings call ends?
Full verbatim transcripts are typically published within 4–12 hours after the call ends. Same-day availability is guaranteed for all S&P 500 and most mid-cap companies.
Is the transcript edited or altered in any way?
No material content is ever changed or summarized in the “Full Transcript” section. We only correct obvious spoken typos (e.g., “um”, “ah”, repeated 10 times”, or clear misspoken ticker symbols) and add speaker names/titles for readability. Every substantive sentence remains 100% as spoken.
Why do some answers appear as “Unclear” or “Inaudible”?
When audio quality is poor or multiple speakers talk over each other, we mark the section instead of guessing. This ensures complete accuracy rather than introducing potential errors.
Who creates the AI Summary and Key Q&A highlights shown above the transcript?
They are generated by a specialized financial-language model trained exclusively on 15+ years of earnings transcripts. The model extracts financial figures, guidance, and tone with 97%+ accuracy and is regularly validated against human analysts. The full raw transcript always remains available for verification.
